Core Viewpoint - The proposed budget cut of $18 billion (40%) to the National Institutes of Health (NIH) by the Trump administration for 2026 is expected to significantly reduce the number of drugs entering the market, with long-term implications for biomedical research and innovation [1][2]. Group 1: Budget Cuts and Impacts - The NIH budget cut, if approved, will take effect on October 1, 2025, and is projected to lead to a reduction of at least 20 drugs entering development over the next 30 years, resulting in a decrease of approximately 4.5% in new drug approvals [1]. - A report from Grant Watch indicates that as of July 3, 2025, 4,473 NIH grant projects are affected, with over $10 billion at risk of funding freeze, primarily impacting research grants [1][2]. Group 2: Talent and Research Environment - The funding cuts may lead to a significant "brain drain," as young researchers may seek opportunities abroad, undermining the U.S.'s leadership in global research [2][3]. - The uncertainty in funding is expected to reduce the number of research institutions and laboratories in the U.S., potentially weakening collaborative capabilities and subsequent innovations [2][3]. Group 3: Regulatory Changes - In addition to budget cuts, the Trump administration has tightened drug approval regulations, including a significant layoff of 3,500 employees at the FDA, which is anticipated to increase the review time for new drug applications by nine months [3].